Therapy News and Research

RSS

Rituximab treatment reduces patients' response to pneumonia vaccine

Researchers from Johns Hopkins University determined that immune responses to the tetanus vaccine were not changed when rituximab in combination with methotrexate (MTX) was compared with MTX alone in patients with rheumatoid arthritis (RA).

7 Jan 2010

Educational sessions and special workshops highlight advancements in molecular imaging

SNM's Conjoint Mid-Winter Meetings, Jan. 27-Feb. 2, 2010, in Albuquerque, N.M., will bring together four scientific meetings under one umbrella. The meeting, which provides attendees with the opportunity to earn up to 25 continuing education credits, will highlight the latest advancements in molecular imaging and nuclear medicine. The educational sessions will conclude with special workshops on nanomedicine and clinical trials.

7 Jan 2010

E-The Environmental Magazine: Environmental toxicity drives up autism rates

As many as one in 90 children are today being diagnosed with autism--and autism research continues to focus almost exclusively on genetics. In its January/February 2010 issue (posted now at: www.emagazine.com), E-The Environmental Magazine looks at another factor that may be driving up autism rates--environmental toxicity.

7 Jan 2010

Diabetes patients with Part D coverage gap are less likely to stick to their medications

Medicare recipients with diabetes who have a gap in their Part D prescription drug benefits—known as the "doughnut hole" — have higher out-of-pocket drug costs and are less likely to stick to their medications than those who have supplemental drug benefits, a new study confirms.

7 Jan 2010

UV LED therapy can be used for treating focal epilepsy in humans

Researchers from the University of Minnesota Medical School discovered that light from an ultraviolet diode (UV LED) reduced "seizure-like" activity in a rat epilepsy model. During the study, UV light released gamma aminobutyric acid (GABA) from the "caged" compound carbonyl amino butanoic acid (BC204).

7 Jan 2010

Authors explain why health care reform initiative should include CER

The current health care reform bills approved by the House and the Senate seek to expand health insurance coverage while containing costs; however, the proposed policy changes are not guaranteed to improve health for individuals or society, according to a "Perspective" article by faculty of Weill Cornell Medical College in the Jan. 6 New England Journal of Medicine.

7 Jan 2010

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

7 Jan 2010

New study reveals music therapy can aid in children's speech acquisition process

Infants who begin hearing after undergoing cochlear implantation have a lot of catching up to do before being able to talk; a new study reveals that music therapy can assist these children's rehabilitation process toward language acquisition

7 Jan 2010

Researchers identify new approach to eliminate side effects of drugs

Researchers at the Stanford University School of Medicine have taken an early step toward identifying a new approach to drug discovery that may eventually yield drugs with fewer side effects.

7 Jan 2010

NCPA offers lawmakers updated health care reform recommendations

With Senate and House leaders trying to craft a health care reform bill to send to the White House, the National Community Pharmacists Association (NCPA) today offered lawmakers updated recommendations for the would-be final legislation.

7 Jan 2010

Antiretroviral therapy improves health outcomes for HIV patients

High antiretroviral therapy adherence, which has been shown to be a major predictor of HIV disease progression and survival, is now associated with lower health care costs, according to researchers at the Johns Hopkins Bloomberg School of Public Health.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, and Genetic Technologies Ltd. (ASX: GTG; NASDAQ: GENE), the leading private genetic testing laboratory in Australia, today announced an exclusive distribution and services agreement.

7 Jan 2010

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

Enzon Pharmaceuticals, Inc. today announced that the first patient has been treated in the Phase 2 studies of PEG-SN38 for metastatic breast cancer. PEG-SN38 or EZN-2208 is Enzon’s PEGylated form of SN38, the active metabolite of the cancer drug Camptosar® (irinotecan HCl injection).

6 Jan 2010

New evidence suggests long-term exposure to cell phone signals may protect against Alzheimer's disease

The millions of people who spend hours every day on a cell phone may have a new excuse for yakking. A surprising new study in mice provides the first evidence that long-term exposure to electromagnetic waves associated with cell phone use may actually protect against, and even reverse, Alzheimer's disease.

6 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

Also in global health news: ART access in Zimbabwe; Indonesia bird flu deaths; Kenya floods; Solomon Island tsunami

Zimbabwe's government plans work with international organizations to increase the number of people receiving anti-retroviral therapy (ART) to 300,000 by the end of the year, up from the 180,000 who currently get the drugs, Henry Madzorera, the country's health minister, said on Tuesday, ZimOnline reports.

6 Jan 2010

Physicians perform first implantation of leadless cardiac monitoring device for detecting arrhythmias

BIOTRONIK SE & Co. KG, the pioneer of wireless remote monitoring technologies and leading manufacturer of implantable cardiac devices, today announced the first implantations of BIOTRONIK’s new leadless cardiac monitoring device performed by a team of physicians led by Professor Dr. Gerhard Hindricks, Director, Electrophysiology Department at the Leipzig Heart Center in Leipzig, Germany.

6 Jan 2010

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a recent "refuse to file" (RTF) letter issued by the Food and Drug Administration (FDA) regarding Merck Serono's oral cladribine has heightened the competition between oral cladribine and its primary competitor, Novartis/Mitsubishi Tanabe's FTY-720 (fingolimod), to be the first oral disease-modifying multiple sclerosis therapy to reach the market in the United States.

6 Jan 2010

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

A comprehensive appraisal of the management and treatment options for low-risk prostate cancer found that the rates of survival and tumor recurrence are similar among the most common treatment approaches, although costs can vary considerably.

6 Jan 2010

Therapy News and Research

Rituximab treatment reduces patients' response to pneumonia vaccine

Educational sessions and special workshops highlight advancements in molecular imaging

E-The Environmental Magazine: Environmental toxicity drives up autism rates

Diabetes patients with Part D coverage gap are less likely to stick to their medications

UV LED therapy can be used for treating focal epilepsy in humans

Authors explain why health care reform initiative should include CER

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

New study reveals music therapy can aid in children's speech acquisition process

Researchers identify new approach to eliminate side effects of drugs

NCPA offers lawmakers updated health care reform recommendations

Antiretroviral therapy improves health outcomes for HIV patients

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Response Genetics and Genetic Technologies sign exclusive distribution and services agreement

Enzon Pharmaceuticals treats first patient in Phase 2 studies of PEG-SN38

New evidence suggests long-term exposure to cell phone signals may protect against Alzheimer's disease

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

Also in global health news: ART access in Zimbabwe; Indonesia bird flu deaths; Kenya floods; Solomon Island tsunami

Physicians perform first implantation of leadless cardiac monitoring device for detecting arrhythmias

Oral cladribine to be the first oral disease-modifying multiple sclerosis therapy despite receiving RTF letter

Similar effectiveness in treatment options for low-risk prostate cancer; research may help improve patient outcomes

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News